- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04383080
The Effect and Safety of Low-level Laser Therapy in Acute Decompensated Heart Failure Patients.
March 22, 2023 updated by: National Yang Ming Chiao Tung University Hospital
The advantages of laser acupuncture are a non-invasive, painless, low risk of infection and high safety.
Laser acupuncture as a treatment tool has the following advantages1.Painless, 2. Non-invasive treatment, the subject is highly accepted, the risk of infection and needle stick is low, 3. Very few side effects such as fainting, bleeding, 4. The therapeutic dose is easy to operate, and the instrument output frequency, power and time can be controlled.
Through the clinical physiological function test plus the verification and analysis of the quantitative test values, it will be more able to define the new role of laser acupuncture treatment in patients with heart failure from the perspective of Chinese medicine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
From the perspective of ancient books, the discussion of heart failure in the etiology and pathogenesis of traditional Chinese medicine was first seen in the "Shu Wen".
It is clearly pointed out that "heart qi" is the basic pathogenesis of heart failure.
The "qi" and "blood" of Chinese medicine are closely related.
The blood line is driven by the gas, the blood is bloody, and the qi deficiency is unable to push the blood to blood.
If the qi deficiency, it would lead to blood stasis; There were studies have indicated that traditional acupuncture treatment can increase exercise tolerance and adjust autonomic nerve activity in patients with chronic heart failure, and can reduce their readmission rate and mortality rate in patients with acute heart failure.
Studies using laser acupuncture to treat patients with heart failure have also found that they can increase the subject's six-minute walking distance.
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Shih Meng Chu, Bachelor
- Phone Number: 886-9-88-283-255
- Email: shihmengchu@gmail.com
Study Locations
-
-
-
Ilan, Taiwan, 26042
- National Yang Ming University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age over 20 years of age, with written informed consent.
- NYHA:stage II-III.
- All patients had LVEF <40% caused by dilated or ischemic cardiomyopathy.
- Acute HF patient presenting with dyspnea related to cardiogenic pulmonary edema.
- All patients had sinus rhythm, were stable and compensated with individually optimized standard heart failure medication as well as oral anticoagulants for at least 3 months before (including prophylactic defibrillator placement).
- Systolic blood pressure > 95 mmHg at admission.
- B-type natriuretic peptide (BNP) > 150 pg/mL or NT-pro BNP > 600 pg/mL.
Exclusion Criteria:
- Age under 20.
- Major cardiovascular events and treatments occurred four weeks before hospitalization.
- Major cardiovascular surgery or treatment will be performed in the next 6 months.
- Pregnant or expected to pregnancy within a year.
- Require a heart transplant in 6 months.
- Uncontrolled atrial or ventricular dysrhythmias.
- Uncompensated congestive heart failure.
- Heart failure due to congenital heart disease or obstructive myocardial disease
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-level laser therapy
Low-level laser irradiation on specific acupuncture points
|
low level laser emission on specific acupuncture points
|
Active Comparator: Acupuncture therapy
Dry needle inserting specific acupuncture points
|
acupuncture at specific acupuncture points
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
N- terminal pro-brain natriuretic peptide, NT-proBNP
Time Frame: At the 12th week and 24th week
|
The change of NT-pro BNP from the date of admission to the end of trial
|
At the 12th week and 24th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
High sensitivity C-Reactive Protein, hs-CRP Hs-CRP
Time Frame: At the 12th week and 24th week
|
The change of NT-pro BNP from the date of admission to the end of trial
|
At the 12th week and 24th week
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionnaires_Instrumental activities of daily living
Time Frame: At the 4th, 12t, 20th and 24th week
|
(IADL);Scoring from 0 to 4 and higher scores mean better outcome.
|
At the 4th, 12t, 20th and 24th week
|
Questionnaires_EuroQol- 5 Dimension
Time Frame: At the 4th, 12t, 20th and 24th week
|
(EQ-5D);Scoring from 1 to 3 and higher scores mean better outcome.
|
At the 4th, 12t, 20th and 24th week
|
Questionnaires_The Minnesota LIVING WITH HEART FAILURE® Questionnaire
Time Frame: At the 4th, 12t, 20th and 24th week
|
(MLHFQ);Scoring from 0 to 5 and higher scores mean better outcome.
|
At the 4th, 12t, 20th and 24th week
|
Questionnaires_Patient Health Questionnaire-9
Time Frame: At the 4th, 12t, 20th and 24th week
|
(PHQ-9);Scoring from 0 to 3 and higher scores mean worse outcome.
|
At the 4th, 12t, 20th and 24th week
|
Questionnaires_Constitution in Chinese Medicine Questionnaire
Time Frame: At the 4th, 12th, 20th and 24th week
|
(CCMQ);Scoring from 1 to 5 and higher scores correspond to specific body constitution.
|
At the 4th, 12th, 20th and 24th week
|
6 minutes walking test
Time Frame: At the 4th, 12t, 20th and 24th week
|
(6 minutes walking distance, meters)
|
At the 4th, 12t, 20th and 24th week
|
Left ventricular ejection fraction
Time Frame: At the 24th week
|
(Ejection fraction, %)
|
At the 24th week
|
Heart rate variability_SDNN
Time Frame: At the 12th and 24th week
|
(Standard deviation of all normal to normal intervals, ms)
|
At the 12th and 24th week
|
Heart rate variability_SDANN index
Time Frame: At the 12th and 24th week
|
(Standard deviation of average normal to normal intervals index, ms)
|
At the 12th and 24th week
|
Heart rate variability_ASDNN
Time Frame: At the 12th and 24th week
|
(Average standard deviation of all 5-min R-R intervals, ms)
|
At the 12th and 24th week
|
Heart rate variability_rMSSD
Time Frame: At the 12th and 24th week
|
(The square root of the mean of the sum of the squares of differences between adjacent NN intervals, ms)
|
At the 12th and 24th week
|
Heart rate variability_LF
Time Frame: At the 12th and 24th week
|
(Low frequency power, normalized unit/ n.u. and ms2)
|
At the 12th and 24th week
|
Heart rate variability_HF
Time Frame: At the 12th and 24th week
|
(High frequency power, normalized unit/ n.u. and ms2)
|
At the 12th and 24th week
|
Heart rate variability_LF/HF
Time Frame: At the 12th and 24th week
|
(LF/HF Ratio)
|
At the 12th and 24th week
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Shih Meng Chu, Bachelor, National Yang Ming Chiao Tung University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2020
Primary Completion (Actual)
December 1, 2022
Study Completion (Actual)
December 17, 2022
Study Registration Dates
First Submitted
April 30, 2020
First Submitted That Met QC Criteria
May 7, 2020
First Posted (Actual)
May 11, 2020
Study Record Updates
Last Update Posted (Actual)
March 24, 2023
Last Update Submitted That Met QC Criteria
March 22, 2023
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NYMUH IRB No.2019b007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
US Department of Veterans AffairsCompleted
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
Clinical Trials on Low-level laser therapy
-
Universidade Federal de Sao CarlosConselho Nacional de Desenvolvimento Científico e TecnológicoCompleted
-
University of Nove de JulhoSimone Aparecida Penimpedo Calamita; Fabiana Sarilho de Mendonça; Daniela Aparecida... and other collaboratorsCompleted
-
University of BergenCompleted
-
University of BergenNorwegian Fund for Postgraduate Training in PhysiotherapyCompleted
-
St. Elisabethen Krankenhaus Frankfurt GmbHRecruitingSurgical Scar Tissue of Cesarean Section or Vaginal Tear or EpisiotomyGermany
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São Paulo; Faculty of Medicine of... and other collaboratorsCompleted
-
University of OttawaBioFlexTM Laser TherapyCompletedProvoked VestibulodyniaCanada
-
NYU Langone HealthCompleted
-
Universidade do Vale do SapucaiCompletedBreast Neoplasms | Radiotherapy; Adverse Effect, Dermatitis or EczemaBrazil
-
University of Nove de JulhoConselho Nacional de Desenvolvimento Científico e TecnológicoNot yet recruitingPain, Postoperative | Endodontically Treated Teeth